A Double-Blind,Randomized,26-Week Study Comparing the Cognitive and Psychomotor Effects and Efficacy of 75 mg (37.5 mg b.i.d.) Venlafaxine and 75 mg (25 mg Mane,50 mg Nocte) Dothiepin in Elderly Patients with Moderate Major Depression Being Treated in General Practice
Restricted accessResearch articleFirst published online June, 2004
A Double-Blind,Randomized,26-Week Study Comparing the Cognitive and Psychomotor Effects and Efficacy of 75 mg (37.5 mg b.i.d.) Venlafaxine and 75 mg (25 mg Mane,50 mg Nocte) Dothiepin in Elderly Patients with Moderate Major Depression Being Treated in General Practice
To investigate the efficacy and cognitive and psychomotor effects of venlafaxine and dothiepin in elderly patients with moderate major depression. A prospective, randomized, double-blind, parallel-group, active comparator controlled study was conducted. Eighty-eight patients (aged ≥ 60 years) were enrolled. Each patient received either venlafaxine (immediate release formulation) 37.5 mg twice per day or dothiepin 25 mg mane followed by 50 mg nocte for 26 weeks. Efficacy was assessed with the Montgomery-Asberg Depression Rating Scale and the Hamilton Depression Rating Scale. A psychometric test battery to assess cognitive function, activities of daily living and sleep consisted of Critical Flicker Fusion (CFF), Short-term Memory - Kim’s Game, Cognitive Failures Questionnaire, Milford Epworth Sleepiness Scale, Leeds Sleep Evaluation Questionnaire, and an Accident Scoring Questionnaire. Quality of Life Questionnaires (Short Form 36 and Quality of Life in Depression Scale) were also administered. Venlafaxine significantly (p < 0.05) raised CFF scores compared to baseline but had no effect on any other measure. Dothiepin significantly (p < 0.05) lowered CFF threshold, and increased ratings of both sedation and difficulty in waking. The results showed that venlafaxine at doses of 37.5 mg b.i.d. in elderly depressed patients is free from disruptive effects on cognitive function and psychomotor performance.
Anderson I M (2001) Meta-analytical studies on new antidepressants . Br Med Bull57: 161-178
2.
Anderson I M , Tomenson B M (1994) The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants . J Psychopharmacol8: 238-249
3.
Anderson I M , Tomenson B M (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis . Br Med J310: 1433-1438
4.
Augustin B G , Cold J A , Jann M W (1997) Venlafaxine and nefazadone, two pharmacologically distinct antidepressants . Pharmacotherapy17: 511-530
5.
Beaumont G , Baldwin D , Lader M (1996) A criticism of the practice of prescribing subtherapeutic doses of antidepressants for the treatment of depression . Hum Psychopharmacol11: 283-291
6.
Benedictis E (2000) Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia . J Psychopharmacol14: 61-66
7.
Brazier J E , Harper R , Jones N N B (1992) Validating the SF36 health survey questionnaire: new outcome measure for primary care . Br Med J305: 160-164
8.
Broadbent D E , Cooper P F , Fitzgerald P , Parkes K R (1982) The cognitive failures questionnaire and its correlates . Br J Clin Psychol21: 1-16
9.
Einarson T R , Arikian S R , Casciano J , Doyle J J (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a metaanalysis of randomized controlled trials . Clin Therapeut21: 296-308
10.
Entsuah A R (2000) Response and remission with venlafaxine, SSRIs, or placebo in subpopulations with major depression . Poster session presented at 10th AEP Congress, Prague
11.
Fairweather D B , Dal Pozzo C , Kerr J S , Lafferty S V , Hindmarch I (1997) Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance . Hum Psychopharmacol Clin Exp12: 119-126
12.
Fairweather D B , Stanley N , Yoon J S , Hindmarch I (1999) The effects of fluoxetine and dothiepin on cognitive function in depressed patients in general practice . Hum Psychopharmacol Clin Exp14: 325-332
13.
Frank E , Prien R F , Jarrett J B (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence . Arch Gen Psychiatry48: 796-800
14.
Hamilton M (1960) A rating scale for depression . J Neurol Neurosurg Psychiatry23: 56-62
15.
Hindmarch I (1975) A 1-4 benzodiazepine, temazepam (K3917), its effect on some psychological parameters of sleep and behaviour . Arzneim Forsch (Drug Research)25: 1836-1839
16.
Hindmarch I (1980) Psychomotor function and psychoactive drugs . Br J Clin Pharmacol10: 189-209
17.
Hindmarch I (1981) Measuring the effect of psychoactive drugs on higher brain activity. In Burrows G , Werry J S (eds), Advances in human psychopharmacology, vol. 2. JAI Press, Connecticut
18.
Hindmarch I (1982) Critical flicker fusion frequency (CFF): the effects of psychotropic compounds . Pharmacopsychiatria15(Suppl 1): 44-48
19.
Hindmarch I (1997) Do we need new antidepressants?Hum Psychopharmacol Clin Exp12: S115-S119
20.
Hindmarch I (1999) The impact of psychotropic medication on daily activities: the behavioural toxicity of antidepressants . Primary Care Psychiatry5: S17-S20
21.
Hindmarch I (2001) Expanding the horizons of depression: beyond the monamine hypothesis . Hum Psychopharmacol Clin Exp16: 203-218
22.
Hindmarch I , Parrott A C (1979) The effects of repeated nocturnal doses of clobazam, dipotassium chlorazepate and placebo on subjective ratings of sleep and early morning behaviour and objective measures of arousal, psychomotor performance and anxiety . Br J Clin Pharmacol8: 325-329
23.
Hindmarch I , Parrott A C , Lanza M (1979) The effects of an ergot alkaloid derivative (hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability . J Clin Pharmacol19: 726-732
24.
Hunt S M , McKenna S P (1992) The QLDS: a scale for the measurement of quality of life in depression . Health Policy22: 307-319
25.
Jenkinson C , Coulter A , Wright L (1993) Short form 36 (SF 36) New England medical center health survey questionnaire: normative data for adults of working age . Br Med J306: 1437-1440
26.
Johns M W (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale . Sleep14: 540-545
27.
Johns M W (1992) Reliability and factor analysis of the Epworth sleepiness scale . Sleep15: 376-381
28.
Kasper S , Heiden A (1995) Do SSRIs differ in their antidepressant efficacy . Hum Psychopharmacol Clin Exp10: S163-S172
29.
Kerr J S , Fairweather D B , Hindmarch I (1997) The effect of paroxetine and dothiepin on subjective sleep in depressed patients . Hum Psychopharmacol Clin Exp12: 71-73
30.
Khan A , Fabre L F , Rudolph R (1991) Venlafaxine in depressed outpatients . Psychopharmacol Bull27: 141-144
31.
Mehtonen O , Søgaard J , Roponen P , Behnke K (2000) Randomized, double-blind comparison of venlafaxine and setraline in outpatients with major depressive disorder . J Clin Psychiatry61: 95-100
32.
Mendels J , Johnston R , Mattes J , Reisenberg R (1993) Efficacy and safety of b.i.d doses of venlafaxine in a dose response study . Psychopharmacol Bull29: 169-174
33.
Montgomery S A , Asberg M (1979) A new depression scale designed to be sensitive to change . Br J Psychiatry134: 382-389
34.
Montgomery S A , Henry J , McDonald G , Dinan T , Lader M , Hindmarch I , Clare A , Nutt D (1994) Selective serotonin reuptake inhibitors: meta analysis of discontinuation rates . Int Clin Psychopharmacol9: 47-53
35.
Montgomery S A , Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a metaanalysis . Int Clin Psychopharmacol9 (Suppl 4): 33-40
36.
Muth E A , Haskins J T , Moyer J A , Husbands G E , Nielsen S T , Sigg S B (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45030, an ethyl cyclohexanol derivative . Biochem Pharmacol35: 4493-4497
37.
Norman T R (1993) Pharmacokinetic aspects of antidepressant treatment in the elderly . Progr Neuropsychopharmacol Biol Psychiatry17: 329-344
38.
O’Hanlon J F , Robbe H W , Vermeeren A , van Leeuwen C , Danjou P E (1998) Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens . J Clin Psychopharmacol18: 212-221
39.
Paes De Sousa M , Figuiera M L , Loureiro F , Hindmarch, I. (1981) Lorazepam and clobazam in anxious elderly patients . Royal Soc Med Int Congr Symp Ser43: 119-123
40.
Pande A C , Sayler M E (1993) Adverse events and treatment discontinuations in fluoxetine clinical trials . Int Clin Psychopharmacol8: 267-269
41.
Parrott A C , Hindmarch I (1978) Factor analysis of a sleep evaluation questionnaire . Psychol Med8: 325-329
42.
Peretti S , Judge R , Hindmarch I (2000) Safety and tolerability considerations: tricyclic antidepressants versus selective serotonin reuptake inhibitors .Acta Psychiatr Scand101(Suppl 403): 17-25
43.
Pinder R M (2001) On the feasibility of designing new antidepressants . Hum Psychopharmacol Clin Exp16: 53-59
44.
Poirier M F (1999) The concept of resistant depression and therapeutic strategies, particularly with venlafaxine . Encephale25: 55-57
45.
Poirier M F , Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison . Br J Psychiatry175: 12-16
46.
Preskorn S H (1993) Recent pharmacologic advances in antidepressant therapy for the elderly . Am J Med94(Suppl 5A): 42-12
47.
Prien R F , Carpenter L L , Kupfer D J (1991) The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature . Arch Gen Psychiatry48: 796-800
48.
Rudolph R L , Feiger A D (1999) A double blind, randomised, placebo-controlled trial of once daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression . J Affect Disord56: 171-181
49.
Schweiser E , Weise C , Clary C , Fox I , Rickels K (1991) Placebo controlled trial of venlafaxine for the treatment of major depression . J Clin Psychopharmacol11: 233-236
50.
Smith D , Dempster C , Glanville J , Freemantle N , Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis . Br J Psychiatry180: 396-404
51.
Snow V , Lascher S , Mottur-Pilson C (2000) Pharmacologic treatment of acute major depression and dysthymia . Annal Int Med132: 738-742
52.
Thase M E , Entsuah A R , Rudolph R L (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors . Br J Psychiatry178: 234-241
53.
Trindade E , Menon D , Topfer L , Coloma C (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis . Can Med Assoc J159: 1245-1252
54.
Tylee A , Beaumont G , Bowden M W , Reynolds A (1997) A double-blind, randomized, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice . Primary Care Psychiatry3: 51-58
55.
Wade A , Despiegel N , Reines E (2002) Depression in primary care patients: improvement during long term escitalopram treatment . Fifteenth ECNP Congress, 5-9 October. Barcelona, Spain
56.
Ware J , Snow W W , Kosinski M , Gandek B (1993) SF-36 health survey: manual and interpretation guide. The Health Institute, Boston, MA
57.
Woodworth R , Schlosberg H (1958) Experimental psychology. Methuen, London
